



Krystal Biotech Announces Five Presentations of Clinical and Preclinical Data at the Society for Investigative Dermatology Annual Meeting

April 29, 2019

PITTSBURGH, April 29, 2019 (GLOBE NEWSWIRE) -- [Krystal Biotech Inc.](#), (“Krystal”) (NASDAQ: KRY5), a gene therapy company developing medicines to treat rare skin diseases announces presentations of clinical data for KB103 to treat dystrophic epidermolysis bullosa, and preclinical data on KB105 for the treatment of autosomal recessive congenital ichthyosis (ARCI) and KB104 for the treatment of Netherton syndrome on May 9, 2019 at the [Society for Investigative Dermatology 77th Annual Meeting](#) in Chicago.

- Dr. Peter Marinkovich, M.D., associate professor of dermatology at Stanford University will present an e-poster entitled “*First in human use of a novel in vivo gene therapy to successfully correct dystrophic epidermolysis bullosa skin: results of a phase 1/2 placebo-controlled trial*” scheduled between 11:15 a.m. - 12:15 p.m. CDT. Dr. Marinkovich will share previously disclosed data from the ongoing GEM-1 placebo-controlled Phase 1/2 clinical study of KB103.
- Pooja Agarwal, Ph.D., vice president of product development for Krystal Biotech will present preclinical data for KB105, an investigational topical gene therapy to treat autosomal recessive congenital ichthyosis (ARCI), between 1:30 p.m. - 4 p.m. CDT. During her presentation entitled “*Preclinical safety and pharmacology of KB105, an HSV-based gene therapy vector for the treatment of autosomal recessive congenital ichthyosis (ARCI)*,” Dr. Agarwal will share data from investigational new drug (IND) enabling studies that support an IND filing by Krystal Biotech, expected 2Q 2019.
- Suma Krishnan, M.S., MBA, founder and chief operating officer at Krystal Biotech, will present an e-poster entitled “*KB104: an HSV-based gene therapy vector engineered to deliver functional SPINK5 for the treatment of Netherton Syndrome*” scheduled between 11:15 a.m. - 12:15 p.m. CDT. Ms. Krishnan will share data from investigational new drug (IND) enabling studies that support an IND filing by Krystal Biotech, expected before EOY 2019.
- Court Freedman, Ph.D., senior scientist at Krystal Biotech will present a poster entitled “*KB105: An HSV-based gene therapy vector engineered to deliver functional TGM1 to Autosomal Recessive Congenital Ichthyosis (ARCI) keratinocytes*” scheduled between 10:45 a.m. – 12:45 p.m. CDT.
- Avijit Mujumdar, Ph.D., senior scientist at Krystal Biotech and Dr. Peipei Zhang, M.D., Ph.D., scientist at Krystal Biotech will present a poster entitled “*Preclinical safety and pharmacology of KB105, an HSV-based gene therapy vector for the treatment of autosomal recessive congenital ichthyosis (ARCI)*” scheduled between 10:45 a.m. – 12:45 p.m. CDT.

About KB103

KB103 (bercolagene telserpavec) is Krystal’s lead product candidate that seeks to use gene therapy to treat dystrophic epidermolysis bullosa, or DEB, an incurable skin blistering condition caused by a lack of collagen in the skin. KB103 is a replication-defective, non-integrating viral vector that has been engineered employing Krystal’s STAR-D platform to deliver functional human COL7A1 genes directly to the patients’ dividing and non-dividing skin cells. HSV-1 is Krystal’s replication-deficient, non-integrating viral vector that can penetrate skin cells more efficiently than other viral vectors. Its high payload capacity allows it to accommodate large or multiple genes and its low immunogenicity makes it a suitable choice for direct and repeat delivery to the skin.

About KB105

KB105 is Krystal’s second product candidate, currently in preclinical development, and seeks to use gene therapy to treat patients with TGM-1 deficient ARCI. KB105 is a replication-defective, non-integrating viral vector that has been engineered employing Krystal’s STAR-D platform to deliver functional human TGM-1 gene directly to the patients’ dividing and non-dividing skin cells. HSV-1 is Krystal’s replication-deficient, non-integrating viral vector that can penetrate skin cells more efficiently than other viral vectors. Its high payload capacity allows it to accommodate large or multiple genes and its low immunogenicity makes it a suitable choice for direct and repeat delivery to the skin.

About Krystal Biotech

Krystal Biotech, Inc. (NASDAQ:KRY5) is a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from dermatological diseases. For more information, please visit <http://www.krystalbio.com>.

Forward-Looking Statements

This press release includes certain disclosures that contain “forward-looking statements,” including, without limitation, statements regarding the potential of KB103 to treat the underlying causes of DEB, the timetable for bringing GMP manufacturing in-house and the potential for rapid development of the company’s clinical programs. You can identify forward-looking statements because they contain words such as “believes” and “expects.” Forward-looking statements are based on Krystal’s current expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth in Krystal’s filings with the Securities and Exchange Commission, including its registration statement on Form S-1 and Form 10-K, as amended from time to time, under the caption “Risk

Factors.”

CONTACTS:

Investors:

Ashley R. Robinson
LifeSci Advisors
arr@lifesciadvisors.com

Media:

Darren Opland, PhD
LifeSci Public Relations
darren@lifescipublicrelations.com

Source: Krystal Biotech, Inc.



Source: Krystal Biotech, Inc.